Canopy Secures $35M Institutional Equity
The TDR Three Key Takeaways:
- Despite cost reductions and operational improvements in most quarters, Canopy Growth faces a significant projected EBITDA loss, necessitating a strategic capital raise.
- The company’s liquidity, when compared with its total financial obligations, is insufficient, leading to a negative Net Current Asset Value per share.
- The participation of institutional investors in Canopy’s recent offering indicates a growing confidence in the company and the broader cannabis industry.
On Thursday, Canopy Growth Corporation revealed its decision to enter into Subscription Agreements with select institutional investors for a private placement offering. The agreement, finalized on January 18, 2024, details the offering of 8,158,510 units at a rate of US$4.29 each, accumulating to an approximate total of US$35 million. This move is primarily aimed at bolstering the company’s liquidity, aligning with its strategic thrust towards reducing overall debt. The proceeds are earmarked for debt repayment, enhancing working capital, and catering to other general corporate needs. This was an update from the news released earlier in the week for a smaller offering.
Each unit in this private placement consists of one common share of the company and a choice between a Series A Common Share purchase warrant or a Series B Common Share purchase warrant. These warrants grant the investors the right to acquire an additional common share at US$4.83. While the Series A warrants are immediately exercisable post the offering closure, the Series B warrants will be exercisable six months post-closure, extending up to five years from the date of the offering. Additionally, investors are provided with customary registration rights, further delineating the terms of this offering.
The closure of this placement is anticipated around January 19, 2024, contingent upon the approval of the Toronto Stock Exchange and the fulfillment of customary closing conditions. It’s pertinent to note that this offering is structured to comply with Rule 135c under the Securities Act of 1933, and as such, it doesn’t represent an open solicitation for buying or selling securities in jurisdictions where such activities are prohibited prior to specific registrations or qualifications under the local securities laws.
My Analysis of the News:
In the past year, Canopy Growth Corporation cautiously raised a limited amount of capital from investors. Despite challenges in boosting revenue (3 Year Revenue CAGR of -0.3%), the company significantly cut expenses, leading to operational improvements in six of the last eight quarters. Yet, Wall Street analysts predict a significant EBITDA loss of $102.5 million USD over the next 12 months. With 89 million shares outstanding, this translates to a loss of more than $1.10 per share in USD.
The liquidity of the company, indicated by $2.42 USD cash per share in the most recent report, is insufficient when considering the overall financial situation, including current assets, liabilities, and total debt. This comprehensive financial view results in a Net Current Asset Value of negative$4.27 per share in USD.
Given these financial conditions, Canopy’s decision to seek additional equity capital through the latest offering is a strategic move. Notably, the presence of institutional investors willing to invest in Canopy reflects a positive sentiment towards the cannabis industry. This trend demonstrates not just Canopy’s proactive financial management but also a broader confidence in the cannabis sector, marking a constructive development in the industry’s investment landscape.